New York: Ireland-based Jazz Pharmaceuticals Plc will buy US-based Celator Pharmaceuticals Inc in a cash deal valued at about $1.5 billion (Dh5.5 billion), to gain access to an investigational product in development for treating acute myeloid leukaemia. Jazz Pharmaceuticals will pay $30.25 per share in cash for Celator, a 72.6 per cent premium to Celator’s closing price on Friday. The deal is expected to add to Jazz Pharma’s non-GAAP adjusted earnings beginning in 2018, the companies said in a statement on Tuesday.